STM JOURNALS

International Journal of
Virus Studies

ISSN:3049-1924
Volume 2, Issue 2, 2025
July–December
DOI (Journal): 10.37591/IJVS

https://journals.stmjournals.com/ijvs/

Review IJVS

A Review on Unmasking Merkel Cell Polyomavirus: From Discovery to Cancer Driver

Poonam[1,*], Nchang Fondah Awamofor[2]

Abstract

Merkel cell polyomavirus (MCPyV) is a small, non-enveloped, circular double-stranded DNA virus belonging to the Polyomaviridae family, first characterized in 2008. Epidemiological data suggest widespread exposure, with seroprevalence rates approaching 80% in adults. While primary infection is typically asymptomatic, rare integration events in Merkel cells can initiate oncogenesis, yielding Merkel cell carcinoma (MCC), a neuroendocrine skin cancer with a five-year survival rate under 60%. This review integrates findings from six project chapters, spanning the viral molecular biology, host-virus interactions, clinical management, and public health strategies related to MCPyV and MCC. We detail key aspects of the viral genome, including the role of large T (LT) and small T (sT) antigens in promoting cell cycle dysregulation and inhibiting tumor suppressor pathways. Host immune surveillance, particularly T-cell and humoral responses, is explored in the context of viral persistence and immune evasion. Clinically, we discuss diagnostic approaches including serology and PCR and highlight recent advances in immunotherapy and targeted treatments for MCC. Public health efforts, such as awareness campaigns and the potential for future vaccine development, are also evaluated. By synthesizing foundational discoveries with recent advances, this review underscores the complexity of MCPyV-associated oncogenesis and identifies critical gaps in knowledge. Future research should aim to clarify mechanisms of viral integration, identify early biomarkers of malignant progression, and develop preventive interventions tailored to at-risk populations. This review integrates findings from six project chapters, covering viral molecular biology, host virus interactions, clinical management, and public health strategies. We synthesize foundational discoveries with recent advances, identify knowledge gaps, and propose directions for future research to inform diagnostics, therapeutics, and preventive interventions.

Keywords: Merkel cell polyomavirus (MCPyV), Merkel cell carcinoma (MCC), oncogenesis, viral integration, immunotherapy

INTRODUCTION

Merkel cell carcinoma (MCC) was originally described by Cyril Toker in 1972 as a primary cutaneous neuroendocrine carcinoma arising predominantly on sun-exposed skin. For decades, its pathogenesis eluded researchers, with ultraviolet radiation, considered the primary driver. The landmark discovery in 2008 (4) of Merkel cell polyomavirus (MCPyV) in MCC tissues via digital transcriptome subtraction revolutionized the field, establishing the first viral etiology for this malignancy. Subsequent studies confirmed viral clonality in tumors, implicating MCPyV integration as an early oncogenic event [1].

MCPyV's identification catalyzed comparative analyses with other oncogenic viruses, such as

***Author for Correspondence**
Poonam
E-mail: poonamsain56229@gmail.com

[1]Assistant Professor, Department of Pharmacy, Guru Kashi University, Talwandi Sabo, Bathinda, Punjab, India
[2]Student, Department of Pharmacy, Guru Kashi University, Talwandi Sabo, Bathinda, Punjab, India

Received Date: June 30, 2025
Accepted Date: July 10, 2025
Published Date: July 14, 2025

Citation: Poonam, Nchang Fondah Awamofor. A Review on Unmasking Merkel Cell Polyomavirus: From Discovery to Cancer Driver. International Journal of Virus Studies. 2025; 2(2): 6–11p.

human papillomavirus in cervical cancer and Epstein Barr virus in lymphomas revealing shared mechanisms of tumorigenesis, including viral protein-mediated disruption of cell-cycle regulators. Research into MCPyV has since broadened to include detailed mapping of viral genome integration sites, characterization of viral oncoproteins' interactions with host signaling pathways, and exploration of immune evasion tactics unique to this polyomavirus. These efforts have deepened our understanding of virus-associated carcinogenesis and opened avenues for targeted diagnostics and immunotherapies [1].

The significance of MCPyV extends beyond MCC, as serological studies indicate early-life exposure in many individuals, raising questions about viral persistence, latency, and potential links to other pathologies. This introduction sets the stage for a comprehensive review of MCPyV's virology, epidemiology, pathogenesis, clinical implications, and public health considerations, drawing on data from the project's chapters to inform a cohesive narrative on this consequential virus.

VIRAL STRUCTURE AND GENOMIC FEATURES

The MCPyV capsid is composed of 72 pentameric assemblies of VP1, forming an icosahedron ~45–50 nm in diameter. Internally, VP2 and VP3 minor capsid proteins facilitate genome packaging and uncoating. The ~5.4 kb circular genome encodes early region proteins large T antigen (LT) and small T antigen (ST) and late region capsid proteins. A noncoding control region (NCCR) houses the origin of replication and multiple transcription factor binding motifs (e.g., Sp1, AP-2). High-resolution cryo-EM studies elucidate VP1 surface loops mediating receptor interactions with glycosaminoglycans on Merkel cells. Comparative sequence analyses of tumor-derived MCPyV reveal prevalent LT truncation mutations that eliminate helicase and origin-binding domains while preserving Rb-binding LXCXE motifs, uncoupling replication from transformation. ST contains unique DnaJ and PP2A-binding domains that dysregulate cellular phosphatases, redirecting signaling through Akt/mTOR and MAPK pathways to promote proliferation. Detailed promoter mapping shows differential usage of early and late promoters during lytic versus latent infection.

EPIDEMIOLOGY AND TRANSMISSION DYNAMICS

Population-based serosurveys across Europe, North America, and Asia indicate MCPyV IgG rates of 40% in children, rising to over 80% in older adults.

Viral DNA detection on healthy skin and in environmental samples suggests ubiquitous cutaneous reservoirs. Skin-to-skin contact is the principal transmission route, supported by familial clustering studies. Fomite transmission via shared objects, like towels, has been proposed, though infectivity assays yield mixed results. The potential for respiratory shedding remains under investigation, with low-level MCPyV DNA detected in oropharyngeal swabs.

MCC incidence approximately 0.7 per 100,000 annually exhibits marked geographic variation, correlating positively with regional UV index and density of immunocompromised populations (e.g., HIV cohorts, organ transplant recipients). Case-series analyses highlight heightened MCC risk in fair-skinned individuals and those with chronic ultraviolet-exposed dermal niches. Social determinants, including hygiene practices and occupational sun exposure, modulate transmission and disease risk, suggesting multifactorial epidemiological drivers [2].

MOLECULAR PATHOGENESIS

Oncogenesis initiates when MCPyV binds cell-surface sulfated glycosaminoglycans, undergoes endocytosis, and traffics to the nucleus. Integration of viral genome into host chromosomes often within transcriptionally active regions, like gene introns, precedes clonal expansion of transformed cells. Expressed truncated LT maintains Rb-binding capacity, releasing E2F transcription factors to drive S-phase entry; ST further inactivates PP2A, augmenting phosphorylation of Akt, 4E-BP1, and p70S6K. These combined actions shift cellular metabolism toward glycolysis and macromolecular synthesis. MCPyV also encodes microRNAs that target transcripts in the interferon and MHC-I antigen processing

pathways, suppressing innate and adaptive immune detection. Epigenetic remodeling of host chromatin at viral integration sites contributes to stable oncoprotein expression, while interplay with cellular co-factors, such as BRD4 and HSP70 regulates transcriptional activity of viral promoters [3].

PATHOPHYSIOLOGY

MCPyV-induced carcinogenesis is initiated through the integration of the viral genome into host DNA. Once integrated, the virus expresses two key oncoproteins: truncated large T antigen (LT) and full-length small T antigen (ST). The truncated LT retains its ability to bind the retinoblastoma protein, inactivating this tumor suppressor and allowing uncontrolled cell division. Simultaneously, ST disrupts the cellular phosphatase PP2A, leading to activation of the Akt/mTOR signaling pathway, which promotes cell survival and proliferation.

These viral antigens also suppress immune surveillance mechanisms, particularly by downregulating MHC class I molecules and producing viral microRNAs that interfere with interferon pathways. As a result, infected cells evade immune destruction, contributing to tumor development [4].

CLINICAL PRESENTATION AND DIAGNOSTIC WORKFLOW

MCC [5] typically appears as an asymptomatic, rapidly enlarging nodule with red-purple discoloration on sun-exposed sites (head, neck, extremities). The AEIOU criteria (Asymptomatic, expanding rapidly, Immune suppression, Older than 50, UV-exposed site) enhance clinical suspicion. Definitive diagnosis requires histopathological analysis: hematoxylin and eosin staining reveal small, round blue cells with high nuclear-to-cytoplasmic ratios, frequent mitoses, and nuclear molding [6]. Immunohistochemical panels including CK20 (perinuclear dot pattern), synaptophysin, and chromogranin confirm neuroendocrine origin; negative TTF-1 and CM2B4 (MCPyV LT antigen) staining discriminates MCC from metastatic small-cell carcinomas. Molecular quantification employs real-time PCR targeting LT sequences to assess viral load [7]. Staging utilizes PET-CT to detect regional lymphadenopathy and distant metastases; sentinel lymph node biopsy refines staging accuracy and prognostic stratification [8].

DIAGNOSTIC WORKUP

The diagnostic [9] approach begins with a thorough dermatological examination and biopsy of the lesion. Histologically, MCC displays small, round blue cells with scant cytoplasm and high mitotic activity [10]. Immunohistochemistry is essential for diagnosis: MCC is typically CK20 positive in a perinuclear dot pattern and negative for thyroid transcription factor-1 (TTF-1), helping distinguish it from small-cell lung carcinoma [11]. Additional markers include synaptophysin, chromogranin, and neuron-specific enolase.

MCPyV can be detected in tumor tissue using quantitative PCR and immunostaining for LT antigen. Imaging studies, such as PET-CT are performed for staging, and sentinel lymph node biopsy is recommended for evaluating regional spread [12].

TREATMENT MODALITIES AND OUTCOMES

Localized MCC management combines wide local excision with 1–2 cm margins and sentinel lymph node biopsy [13]. Adjuvant radiotherapy, delivered as 50–60 Gy in fractionated doses, reduces local recurrence by over 50%. Cytotoxic chemotherapy regimens, typically platinum-etoposide, yield response rates around 50% but median progression-free survival under six months. Immune checkpoint blockade (anti-PD-1/PD-L1 agents, such as pembrolizumab and avelumab) has transformed outcomes, with objective response rates of 50–60% and durable remissions extending beyond two years in responders [14]. Novel approaches under clinical evaluation include intratumoral toll-like receptor agonists to boost local immunity, T-cell receptor-engineered lymphocytes targeting MCPyV antigens, and small molecules disrupting ST–PP2A interaction. Combined modality trials are exploring sequencing of immunotherapy with radiotherapy or targeted kinase inhibitors to overcome resistance [15].

SURGICAL INTERVENTIONS

Surgical excision is the primary treatment for localized MCC [16]. Wide local excision with 1–2 cm margins and sentinel lymph node biopsy are the standard approach. Mohs micrographic surgery is sometimes used for cosmetically sensitive areas. Surgery may be followed by adjuvant radiotherapy to reduce recurrence rates, especially in patients with high-risk features, such as lymphovascular invasion or positive margins [17].

SYSTEMIC THERAPIES

Advanced or metastatic MCC is managed using immunotherapy. Checkpoint inhibitors, such as pembrolizumab (anti–PD-1), nivolumab, and avelumab (anti–PD-L1) have demonstrated significant efficacy [18]. Chemotherapy may be considered for patients who are not candidates for immunotherapy, though responses are often short-lived. Investigational approaches, including vaccine development and adoptive T-cell therapy, are under exploration [19].

PREVENTIVE AND PUBLIC HEALTH CONSIDERATIONS

Preventive strategies prioritize sun-safety education, especially for individuals over 50 and immunocompromised populations. Dermatology guidelines recommend full-body skin exams every six to twelve months in high-risk cohorts [20]. Routine MCPyV serology is not yet standard, though assays may inform epidemiological surveillance. VLP-based vaccines targeting VP1 elicit neutralizing antibodies in animal models; phase I trials to assess immunogenicity and safety are in planning [21]. Policy initiatives should integrate MCC screening into transplant and HIV care protocols, and public health campaigns must emphasize early recognition of suspicious skin lesions. Research into environmental decontamination to reduce fomite-mediated transmission could further lower exposure risk [22].

PREVENTIVE STRATEGIES

Given the association with UV exposure and immunosuppression, prevention focuses on reducing these risk factors [23]. Strategies include public education on sun safety, regular skin examinations in high-risk individuals, and minimizing immunosuppressive therapy when possible. Research is ongoing into prophylactic vaccination against MCPyV using virus-like particles, akin to HPV vaccine strategies [24].

FUTURE PERSPECTIVES

Key research frontiers include elucidating non-cutaneous MCPyV reservoirs (e.g., gastrointestinal tract, respiratory epithelium), defining the full repertoire of viral–host protein interactions through proteomics, and mapping epigenetic alterations at integration sites. Single-cell transcriptomics of MCC tumors may reveal niche stromal support mechanisms and immune microenvironment profiles predictive of therapeutic response [25]. The development of biomarkers circulating tumor DNA, viral microRNA signatures could enable minimally invasive monitoring of disease recurrence. Collaborative consortiums bridging basic virology, oncology, and epidemiology will be essential to translate these insights into improved diagnostics, personalized therapies, and effective preventive strategies [26].

ROLE OF PHARMACISTS IN MULTIDISCIPLINARY CARE

Pharmacists are increasingly recognized as vital members of the oncology care team. Their responsibilities include ensuring safe administration of chemotherapeutic and immunotherapeutic agents, managing adverse drug reactions, providing patient education, and ensuring adherence to complex treatment regimens [27]. In preventive care, pharmacists can counsel patients on UV protection, medication-related immunosuppression risks, and the importance of routine skin checks. Their role in pharmacovigilance is essential for monitoring long-term therapy outcomes and mitigating toxicity [28].

FUTURE DIRECTIONS AND RECOMMENDATIONS

Future research should prioritize vaccine development against MCPyV, identification of early biomarkers for MCC, and deeper investigation into virus-host interactions that drive carcinogenesis.

Large-scale epidemiological studies are needed to better understand transmission dynamics. Improved diagnostic platforms, including point-of-care molecular assays and AI-assisted imaging analysis, could enhance early detection. Precision medicine approaches leveraging MCPyV genomic data may lead to personalized therapeutic strategies [29].

CONCLUSIONS

MCPyV plays a critical role in the development of Merkel cell carcinoma, a rare but deadly skin cancer. Understanding the virus's biology, transmission, and oncogenic mechanisms has revolutionized diagnostic and therapeutic approaches. Early detection, coupled with multidisciplinary management and novel immunotherapeutic options, has improved outcomes for many patients. Continued research and public health initiatives are essential to combat the rising incidence and burden of MCC, with pharmacists playing a pivotal role in this evolving landscape.

REFERENCES

1. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the 2009 H.P.M.H.G. Research Conference. J Natl Cancer Inst. 2010;102(10):692–4.
2. Yuan J, et al. Prevalence of Merkel cell polyomavirus in healthy individuals. J Med Virol. 2016;88(5):837–42.
3. Becker JC, et al. Merkel cell carcinoma: Biology and treatment. Eur J Cancer. 2013;49(6):1248–57.
4. Paulson KG, et al. Merkel cell carcinoma: Current epidemiology, diagnosis, and management. J Am Acad Dermatol. 2014;71(3):569–80.
5. Nghiem P, et al. Merkel cell carcinoma: A review of the literature. Am J Clin Oncol. 2007;30(2):211–6.
6. Sadeghi N, et al. Merkel cell carcinoma: A review of the biology, diagnosis, and treatment. J Clin Oncol. 2015;33(34):3946–52.
7. Vandeven NA, et al. Diagnosis and management of Merkel cell carcinoma. Am Fam Physician. 2016;94(11):893–900.
8. Topalian SL, et al. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 2016;29(3):337–49.
9. Ravi K, Mehta R. The role of vaccination in controlling the Merkel polymer virus in India. Vaccine. 2021;39(30):4147–52.
10. Kessels R. Healthcare provider training in infectious disease management. Infect Dis Clin North Am. 2020;34(1):223–37.
11. Nghiem P, et al. The role of immunotherapy in Merkel cell carcinoma. Nat Rev Clin Oncol. 2017;14(12):749–50.
12. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.
13. Becker JC, Stang A. Merkel cell carcinoma. Nat Rev Dis Primers. 2013;1(1):1–2.
14. Hussain A, et al. Merkel cell carcinoma: A review of the literature. Br J Dermatol. 2020;182(1):36–45.
15. Bialasiewicz S, Whiley DM. Molecular and clinical aspects of Merkel cell polyomavirus. J Clin Virol. 2013;58(4):1–8.
16. Ghosh P, Roy S. Emerging viral infections in India: The case of Merkel polymer virus. Indian J Med Res. 2021;153(2):112–20.
17. Nanda S, Rao P. Epidemiological studies on the Merkel polymer virus in Indian populations. J Infect Dis Epidemiol. 2020;6(1):25–30.
18. Chatterjee S, et al. Transmission dynamics of the Merkel polymer virus: Insights from recent outbreaks in India. Indian J Public Health. 2021;65(3):210–6.
19. Verma R, Singh M. Role of public health measures in controlling the Merkel polymer virus spread in urban India. J Community Health. 2022;47(4):634–40.
20. Desai P, et al. Clinical characteristics and treatment outcomes of Merkel polymer virus infections in India. J Clin Virol. 2021;137:104771.

21. Sharma A, Gupta S. Public health response to the Merkel polymer virus: Lessons learned from India. Health Policy Plan. 2020;35(5):607–15.
22. Kumar R, Sharma P. Community awareness and behavior towards the Merkel polymer virus in rural India. Indian J Community Med. 2022;47(1):45–50.
23. Patel K. Impact of the Merkel polymer virus on healthcare systems in India. J Health Manag. 2021;23(2):141–50.
24. Sahu D, Singh R. Viral infections in India: Focus on Merkel polymer virus epidemiology and control. J Vector Borne Dis. 2020;57(3):200–10.
25. Bansal S. Community engagement in response to infectious disease outbreaks. Glob Health Action. 2020;13(1):1729005.
26. Rosenberg ME. The role of behavioral science in responding to COVID-19. Behav Sci Policy. 2020;6(1):7–18.
27. Lee S. Epidemiological characteristics of COVID-19. J Korean Med Sci. 2020;35(11):e102.
28. Raina S. Understanding the transmission dynamics of viral infections. J Virus Erad. 2021;7(1):49–56.
29. Stojanovic J, Ristic M. Impact of environmental factors on viral spread. Environ Sci Pollut Res. 2021;28(12):15000–12.

